Yüklüyor......
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
The approval of sorafenib, a multikinase inhibitor targeting primarily Raf kinase and the vascular endothelial growth factor receptor, in 2007 for treating advanced hepatocellular carcinoma (HCC) has generated considerable enthusiasm in drug development for this difficult-to-treat disease. However,...
Kaydedildi:
| Yayımlandı: | J Hepatocell Carcinoma |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918267/ https://ncbi.nlm.nih.gov/pubmed/27508178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S45040 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|